Project Grant R01AT013147
Award Date
4/15/25
Completion Date
1/31/30
Dollars Obligated
$631K
Federal Agency
National Center for Complementary and Integrative Health
Federal Grant Program
93.213
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $205,700 to the Sloan-Kettering Institute for Cancer Research to conduct research aimed at understanding and overcoming rapid resistance to targeted therapies in colorectal cancer. The key objectives are to evaluate how intrinsic tumor features modulate the development of resistance to targeted therapies, and to test a novel combination approach involving DNA repair inhibition...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $158,020.00 in funding to the Sloan-Kettering Institute for Cancer Research to investigate the role of mutagenic DNA repair during the persistence of cancer cells. The key products and services to be delivered under this award include: Investigating persistence in response to PARP inhibitor treatment of BRCA1/2 mutant cancer cells to understand the mechanisms of mutagenic DNA repair,...
This Project Grant award of $1,220,394 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research will fund a comprehensive research project to investigate the acute and chronic neurotoxicity associated with chimeric antigen receptor (CAR) T-cell therapy. The research aims to deepen the understanding of the neurological complications, known as immune effector cell-associated neurotoxicity syndrome (ICANS), that can occur in...
The federal Project Grant award R01CA300788, provided by the National Cancer Institute (NCI) under the CFDA 93.396 Cancer Biology Research program, supports research on the relationship between inflammatory signaling in the leptomeninges (the membranes surrounding the brain and spinal cord) and the growth of leptomeningeal metastases, a lethal complication of cancer. The $730,398 award to the Sloan-Kettering Institute for Cancer Research will leverage the institute's collection of clinical...
This $577,034 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Sloan-Kettering Institute for Cancer Research will support a 5-year research project investigating the relationship between the physical properties of tumor microenvironments and the ability of cytotoxic lymphocytes to recognize and destroy cancer cells. The researchers will use innovative biophysical approaches, including the suspended microchannel resonator (SMR) technology, to...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program will support a multilevel intervention to improve communication between healthcare providers and patients about the use of complementary and alternative medicine (CAM) for cancer treatment. The $388,800 award to HMH Hospitals Corporation, doing business as Hackensack University Medical Center, will be used to: 1) engage providers and patients to develop a CAM-focused...
This federal Project Grant award of $432,168.00 from the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program supports research at the Sloan-Kettering Institute for Cancer Research in New York, NY. The project aims to develop computational models that can quantitatively predict how clinical kinase mutations impact drug resistance, activity, and sensitivity in cancer treatment. Specifically, the research will utilize binding free-energy calculations and...
This federal Project Grant award of $2,808,108.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the Sloan-Kettering Institute for Cancer Research to investigate the role of clonal hematopoiesis in therapeutic resistance and metastatic relapse in breast cancer. The award period extends from March 1, 2024 to February 29, 2028. Through this funding, the Sloan-Kettering Institute will explore the...
The National Cancer Institute (NCI) awarded a $483,395 Project Grant (CFDA 93.395 Cancer Treatment Research) to The Institute For Cancer Research, a non-profit research organization located in Cheltenham, Pennsylvania. The funding will support the development and evaluation of a novel engineered IL-21-based immunocytokine as a therapeutic approach for tumor targeting in renal cell carcinoma (RCC). Specifically, the project aims to: (1) develop a humanized anti-CD70-IL-21 fusion antibody with...
The National Cancer Institute awarded a $375,134 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Colorado-Denver. The grant supports research to reduce off-target accumulation of chemotherapeutic nanomedicines and improve the efficacy of cancer chemotherapy. Key objectives include characterizing an innate immune response that can limit nanoparticle deposition in healthy tissues, and exploring the potential to utilize this response to enable more...